| Combigan (brimonidine tartrate/timolol maleate) / AbbVie |
NCT00332436: Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension |
|
|
| Completed | 3 | 586 | US | brimonidine/timolol fixed combination | Allergan | Ocular Hypertension | 11/01 | 11/01 | | |
NCT00332384: Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension |
|
|
| Completed | 3 | 573 | US | brimonidine/timolol fixed combination | Allergan | Ocular Hypertension | 11/01 | 11/01 | | |
NCT00652106: Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension |
|
|
| Completed | 3 | 432 | US | 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, COMBIGAN®, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution, ALPHAGAN® | Allergan | Glaucoma, Ocular Hypertension | 03/04 | 03/04 | | |
NCT00651612: Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients |
|
|
| Completed | 3 | 604 | US | Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, COMBIGAN™, Concurrent brimonidine 0.2% and 0.5% timolol | Allergan | Glaucoma, Ocular Hypertension | 01/07 | 01/07 | | |
2005-004060-24: A double-masked randomized cross-over study comparing the effect of Xalacom (latanoprost/timolol) and Combigan (brimonidine/timolol) fixed combination on intraocular pressure and ocular blood flow in patients with primary open angle glaucoma or ocular hypertension |
|
|
| Completed | 3 | 20 | Europe | Eye drops*, , Xalacom, Combigan | Department of Clinical Pharmacology | Glaucoma | | 08/11 | | |
NCT01241240: Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 3 | 192 | RoW | bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution, COMBIGAN® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 09/13 | 09/13 | | |
NCT01217606: Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 3 | 185 | RoW | bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution, COMBIGAN® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 09/14 | 06/15 | | |
2015-000160-34: This study will evaluate and confirm that the efficacy and tolerability of a New Preservative-free Generic Formulation of 0.2% Brimonidine/0.5% Timolol fixed-Combination Eye Drops solution in single dose container is not worse to the marketed preservative-containing formulation Combigan®Eye Drops solution in Patients with OpenAngle Glaucoma or Ocular Hypertension already on Treatment with IOP-lowering Drugs and Low Intraocular Pressure (IOP≤21 mmHg) Η μελέτη αυτή θα τεκμηριώσει ότι η αποτελεσματικότητα και ανεκτικότητα ενός νέου άνευ συντηρητικού γενοσήμου σκευάσματος σταθερού συνδυασμόυ 0.2% Βριμονιδίνης/0.5% Τιμολόλης οφθαλμικές σταγόνες δεν είναι κατώτερη από το εγκεκριμένο σκευάσμα Combigan® οφθαλμικές σταγόνες που περιέχει συντηρητικό σε ασθενείς με Γλαύκωμα Ανοικτής Γωνίας ή Οφθαλμική Υπερτονία οι οποίοι είναι ήδη σε θεραπεία μείωσης της Ενδοφθάλμιας Πίεσης (ΕΠ) και παρουσιάζουν χαμηλή Ενδοφθάλμια Πίεση (ΕΠ≤21 mmHg). |
|
|
| Completed | 3 | 180 | Europe | Preservative-free 0.2% Brimonidine/0.5% Timolol Eye Drops, Eye drops, solution in single-dose container, Eye drops, solution, Combigan® | OmniVision GmbH, OmniVision GmbH | Open angle glaucoma or ocular hypertension. Γλαύκωμα Ανοικτής Γωνίας ή Ενδοφθάλμια Υπερτονία, Open angle glaucoma is characterized by increased intraocular pressure, resulting in pathological changes in the optic disk and typical visual field defects, and eventually blindness. To γλαύκωμα ανοικτής γωνίας χαρακτηρίζεται από αυξημένη ενδοφθάλμια πίεση η οποία έχει ως αποτέλεσμα παθολογικές αλλαγές στον οπτικό δίσκο και τυπικά ελλείμματα του οπτικού πεδίου και τελικώς τύφλωση, Diseases [C] - Eye Diseases [C11] | | | | |
NCT03235232: BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension |
|
|
| Completed | 3 | 406 | RoW | BREMEN eye drops, Combigan® | EMS | Ocular Hypertension, Primary Open-angle Glaucoma | 07/23 | 10/23 | | |
